Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, People's Republic of China.
Department of Hematology; First Affiliated Hospital, Jinan University, Guangzhou, People's Republic of China.
Hematology. 2021 Dec;26(1):210-214. doi: 10.1080/16078454.2021.1880734.
Previous study ( 2017; 176:498) reported that CD56 positive is associated with poor prognosis of patients with intermediate-risk acute myeloid leukemia (IR-AML). However, our data were inconsistent with the finding Thus, in this study, we provided the different results to discuss.
A total of 262 bone marrow transcriptomic data of IR-AML in the GSE12417-GPL96 and GSE71014-GPL-10558 from the Gene Expression Omnibus database (GEO) database, and 92 IR-AML patients from the cancer genome atlas (TCGA) database were obtained for prognostic analysis and validation.
Compared with low CD56 expression, IR-AML patients with high CD56 expression had a longer overall survival (OS) time and restricted mean survival time (RMST) and favorable OS rate in the GSE12417-GPL96 dataset. These results were confirmed in both GSE71014-GPL-10558 and TCGA datasets. Importantly, the inconsistency between our findings and the previous finding may be due to the following reasons: different detection methods, age stratification, countries, treatment options etc.
The prognostic value of CD56 expression in IR-AML may need to be comprehensively evaluated based on different detection methods, age stratification, countries, treatment options, and other factors. If confirmed, CD56 may be a biomarker for further risk stratification for IR-AML patients.
先前的研究（2017 年；176：498）表明，CD56 阳性与中危急性髓系白血病（IR-AML）患者的预后不良相关。然而，我们的数据与这一发现不一致。因此，在本研究中，我们提供了不同的结果进行讨论。
从基因表达综合数据库（GEO）数据库中获取了 262 例 IR-AML 患者的骨髓转录组数据（GSE12417-GPL96 和 GSE71014-GPL-10558），并从癌症基因组图谱（TCGA）数据库中获取了 92 例 IR-AML 患者的数据进行预后分析和验证。
与低 CD56 表达相比，GSE12417-GPL96 数据集中高 CD56 表达的 IR-AML 患者总生存期（OS）时间和限制平均生存时间（RMST）更长，OS 率更高。这些结果在 GSE71014-GPL-10558 和 TCGA 数据集中均得到了证实。重要的是，我们的发现与先前发现之间的不一致可能是由于以下原因：不同的检测方法、年龄分层、国家、治疗选择等。
CD56 表达在 IR-AML 中的预后价值可能需要基于不同的检测方法、年龄分层、国家、治疗选择等因素进行综合评估。如果得到证实，CD56 可能成为进一步对 IR-AML 患者进行风险分层的生物标志物。
